The Prurigo drugs in development market research report provides comprehensive information on the therapeutics under development for Prurigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Prurigo. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Prurigo - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Prurigo and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Prurigo by ten companies/universities/institutes. The top development phase for Prurigo is phase i with four drugs in that stage. The Prurigo pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Prurigo pipeline products market are: Incyte, JiangSu Qyuns Therapeutics and Maruho.

The key targets in the Prurigo pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC, Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC, and Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R).

The key mechanisms of action in the Prurigo pipeline product include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC Inhibitor with three drugs in Phase III. The Prurigo pipeline products include five routes of administration with the top ROA being Subcutaneous and three key molecule types in the Prurigo pipeline products market including Monoclonal Antibody, and Small Molecule.

Prurigo overview

Prurigo nodularis (PN) is a skin disease characterized by pruritic (itchy) nodules that usually appear on the arms or legs. It is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques, and nodules commonly located on the extensor surfaces of the extremities. The exact cause of PN is unknown. The condition may be diagnosed based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis.

For a complete picture of Prurigo’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.